Tessa Romero
Stock Analyst at JP Morgan
(3.86)
# 636
Out of 4,876 analysts
62
Total ratings
46.81%
Success rate
12.11%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tessa Romero
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BHVN Biohaven | Maintains: Overweight | $68 → $55 | $14.74 | +273.13% | 7 | Jun 18, 2025 | |
| CYTK Cytokinetics | Maintains: Overweight | $71 → $53 | $33.91 | +56.30% | 5 | Jun 9, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Overweight | $26 → $30 | $22.21 | +35.07% | 7 | Jun 6, 2025 | |
| LXEO Lexeo Therapeutics | Maintains: Overweight | $16 → $10 | $4.18 | +139.23% | 2 | May 30, 2025 | |
| DYN Dyne Therapeutics | Maintains: Neutral | $18 → $17 | $10.05 | +69.15% | 5 | Mar 21, 2025 | |
| UPB Upstream Bio | Initiates: Overweight | $38 | $10.94 | +247.35% | 1 | Nov 5, 2024 | |
| NMRA Neumora Therapeutics | Downgrades: Neutral | $18 → $15 | $0.80 | +1,776.41% | 4 | Nov 5, 2024 | |
| MCRB Seres Therapeutics | Downgrades: Underweight | n/a | $9.51 | - | 2 | Oct 24, 2024 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $18 → $31 | $35.48 | -12.63% | 5 | Oct 14, 2024 | |
| EYPT EyePoint Pharmaceuticals | Maintains: Overweight | $32 → $29 | $10.37 | +179.65% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $31 | $13.06 | +137.37% | 8 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $46 | $33.65 | +36.70% | 6 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $8 → $7 | $4.78 | +46.44% | 5 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $55 | $32.20 | +70.81% | 2 | Apr 25, 2023 |
Biohaven
Jun 18, 2025
Maintains: Overweight
Price Target: $68 → $55
Current: $14.74
Upside: +273.13%
Cytokinetics
Jun 9, 2025
Maintains: Overweight
Price Target: $71 → $53
Current: $33.91
Upside: +56.30%
ACADIA Pharmaceuticals
Jun 6, 2025
Maintains: Overweight
Price Target: $26 → $30
Current: $22.21
Upside: +35.07%
Lexeo Therapeutics
May 30, 2025
Maintains: Overweight
Price Target: $16 → $10
Current: $4.18
Upside: +139.23%
Dyne Therapeutics
Mar 21, 2025
Maintains: Neutral
Price Target: $18 → $17
Current: $10.05
Upside: +69.15%
Upstream Bio
Nov 5, 2024
Initiates: Overweight
Price Target: $38
Current: $10.94
Upside: +247.35%
Neumora Therapeutics
Nov 5, 2024
Downgrades: Neutral
Price Target: $18 → $15
Current: $0.80
Upside: +1,776.41%
Seres Therapeutics
Oct 24, 2024
Downgrades: Underweight
Price Target: n/a
Current: $9.51
Upside: -
Scholar Rock Holding
Oct 14, 2024
Maintains: Overweight
Price Target: $18 → $31
Current: $35.48
Upside: -12.63%
EyePoint Pharmaceuticals
Aug 13, 2024
Maintains: Overweight
Price Target: $32 → $29
Current: $10.37
Upside: +179.65%
Aug 12, 2024
Maintains: Overweight
Price Target: $30 → $31
Current: $13.06
Upside: +137.37%
Jun 13, 2024
Reinstates: Neutral
Price Target: $46
Current: $33.65
Upside: +36.70%
Aug 22, 2023
Maintains: Underweight
Price Target: $8 → $7
Current: $4.78
Upside: +46.44%
Apr 25, 2023
Maintains: Overweight
Price Target: $54 → $55
Current: $32.20
Upside: +70.81%